ZACKS INVESTMENT MANAGEMENT - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 277 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.

Quarter-by-quarter ownership
ZACKS INVESTMENT MANAGEMENT ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2023$1,115,016
+39.6%
15,569
+1.5%
0.01%
+40.0%
Q3 2023$798,729
+24.9%
15,334
+51.9%
0.01%
+25.0%
Q2 2023$639,341
+18.2%
10,097
+1.1%
0.01%
+14.3%
Q1 2023$541,012
+15.3%
9,991
+12.7%
0.01%0.0%
Q4 2022$469,040
+18.7%
8,863
+4.4%
0.01%
+16.7%
Q3 2022$395,000
-3.7%
8,486
+18.1%
0.01%0.0%
Q2 2022$410,0007,1840.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 360,000$11,502,0002.65%
Redmile Group, LLC 610,171$19,495,0001.60%
Pier Capital, LLC 257,256$8,219,0001.18%
WALL STREET ASSOCIATES 358,857$11,465,0001.08%
SENZAR ASSET MANAGEMENT, LLC 161,300$5,154,0000.88%
Rhenman & Partners Asset Management AB 206,000$6,582,0000.79%
EAM Investors, LLC 152,389$4,869,0000.57%
EDMOND DE ROTHSCHILD (SUISSE) S.A. 50,000$1,598,0000.51%
Visium Asset Management, LP 1,051,479$33,595,0000.48%
SPHERA FUNDS MANAGEMENT LTD. 128,000$4,090,0000.40%
View complete list of INTRA CELLULAR THERAPIES INC shareholders